Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells

References

• Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550–554. doi:10.1038/315550a0
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–2264. doi:10.1172/JCI41246
   PubMed Web of Science ®Google Scholar
• Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18(4):930–937. doi:10.1158/1078-0432.CCR-10-1613
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876–880. doi:10.1126/science.1062538
   PubMed Web of Science ®Google Scholar
• Kashige N, Carpino N, Kobayashi R. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity. Proc Natl Acad Sci U S A. 2000;97(5):2093–2098. doi:10.1073/pnas.040547997
   PubMed Web of Science ®Google Scholar
• Bavaro L, Martelli M, Cavo M, et al. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci. 2019;20(24):6141. doi:10.3390/ijms20246141
   PubMed Web of Science ®Google Scholar
• Houshmand M, Simonetti G, Circosta P, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33(7):1543–1556. doi:10.1038/s41375-019-0490-0
   PubMed Web of Science ®Google Scholar
• Loscocco F, Visani G, Galimberti S, et al. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol. 2019;9:939. doi:10.3389/fonc.2019.00939
   PubMed Web of Science ®Google Scholar
• Moradi F, Babashah S, Sadeghizadeh M, et al. Signaling pathways involved in chronic myeloid leukemia pathogenesis: the importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells. Iran J Basic Med Sci. 2019;22(6):581–589. doi:10.22038/ijbms.2019.31879.7666
   PubMed Web of Science ®Google Scholar
• Nie ZY, Yao M, Yang Z, et al. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance. J Exp Clin Cancer Res. 2020;39(1):17. doi:10.1186/s13046-019-1502-7
   PubMed Web of Science ®Google Scholar
• Wang X, Bi X, Huang X, et al. Systematic investigation of biomarker-like role of ARHGDIB in breast cancer. Cancer Biomark. 2020;28(1):101–110. doi:10.3233/CBM-190562
   PubMed Web of Science ®Google Scholar
• Wang P, Yang X, Wu P, et al. GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells. Oncology. 2007;73(5-6):430–438. doi:10.1159/000136801
   PubMed Web of Science ®Google Scholar
• Yi B, Hu Y, Qin G, et al. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. Int J Mol Med. 2014;34(1):205–212. doi:10.3892/ijmm.2014.1765
   PubMed Web of Science ®Google Scholar
• Xia B, Wang J. Adenosine inhibits ovarian cancer growth through regulating RhoGDI2 protein expression. Drug Des Devel Ther. 2019;13:3837–3844. doi:10.2147/DDDT.S219028
   PubMed Web of Science ®Google Scholar
• Cho HJ, Baek KE, Park SM, et al. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011;311(1):48–56. doi:10.1016/j.canlet.2011.06.024
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang W, Yu K, et al. Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer. FASEB J. 2022;36(8):e22465. doi:10.1096/fj.202101658R
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim IK, Park SM, et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer. 2014;135(7):1553–1563. doi:10.1002/ijc.28801
   PubMed Web of Science ®Google Scholar
• Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–2914. doi:10.1093/bioinformatics/btv300
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442–459. doi:10.1002/ajh.25011
   PubMed Web of Science ®Google Scholar
• Cortes J, Pavlovsky C, Saußele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914–1926. doi:10.1016/S0140-6736(21)01204-6
   PubMed Web of Science ®Google Scholar
• Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14(1):44. doi:10.1186/s13045-021-01055-9
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang P, Song T, et al. Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study. Hematology. 2021;26(1):408–414. doi:10.1080/16078454.2021.1931740
   PubMed Web of Science ®Google Scholar
• Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 2001;15(8):1232–1239. doi:10.1038/sj.leu.2402179
   PubMed Web of Science ®Google Scholar
• Weisberg E, Wright RD, McMillin DW, et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008;7(5):1121–1129. doi:10.1158/1535-7163.MCT-07-2331
   PubMed Web of Science ®Google Scholar
• Guo-Bao W, Xiao-Qin C, Qi-Rong G, et al. Arsenic trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. Leuk Lymphoma. 2010;51(6):1090–1097. doi:10.3109/10428191003746315
   PubMed Web of Science ®Google Scholar
• Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28. doi:10.1186/s12943-021-01316-8
   PubMed Web of Science ®Google Scholar
• Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation- have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261–279. doi:10.1038/s41571-020-00459-9
   PubMed Web of Science ®Google Scholar
• Deets KA, Vance RE. Inflammasomes and adaptive immune responses. Nat Immunol. 2021;22(4):412–422. doi:10.1038/s41590-021-00869-6
   PubMed Web of Science ®Google Scholar
• Abraham SA, Hopcroft LE, Carrick E, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534(7607):341–346. doi:10.1038/nature18288
   PubMed Web of Science ®Google Scholar
• von Klot CA, Dubrowinskaja N, Peters I, et al. Rho GDP dissociation inhibitor-β in renal cell carcinoma. Oncol Lett. 2017;14(6):8190–8196. doi:10.3892/ol.2017.7233.
   PubMed Web of Science ®Google Scholar
• Niu H, Li H, Xu C, et al. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep. 2010;24(2):465–471. doi:10.3892/or_00000880
   PubMed Web of Science ®Google Scholar
• Zhu J, Tian Z, Li Y, et al. ATG7 promotes bladder cancer invasion via autophagy-mediated increased ARHGDIB mRNA stability. Adv Sci (Weinh). 2021;8(22):e2104365. doi:10.1002/advs.202104365
   PubMedGoogle Scholar
• Ma L, Xu G, Sotnikova A, et al. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Br J Haematol. 2007;139(2):217–223. doi:10.1111/j.1365-2141.2007.06782.x
   PubMed Web of Science ®Google Scholar
• Liu L, Cui J, Zhao Y, et al. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. Mol Cancer. 2021;20(1):77. doi:10.1186/s12943-021-01369-9
   PubMed Web of Science ®Google Scholar
• Harding MA, Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol. 2007;25(5):401–406. doi:10.1016/j.urolonc.2007.05.006
   PubMed Web of Science ®Google Scholar